Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Sep;49(11):3841-3851.
doi: 10.1007/s00259-022-05792-y. Epub 2022 May 3.

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Aleksandra Syguła  1 , Aleksandra Ledwon  1 , Kornelia Hasse-Lazar  1 , Beata Jurecka-Lubieniecka  1 , Barbara Michalik  1 , Ewa Paliczka-Cieślik  1 , Marcin Zeman  2 , Ewa Chmielik  3 , Joanna Sczasny  4 , Barbara Jarzab  1 , Daria Handkiewicz-Junak  5
Affiliations
Randomized Controlled Trial

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Aleksandra Syguła et al. Eur J Nucl Med Mol Imaging. 2022 Sep.

Abstract

Purpose: Peptide receptor radionuclide therapy (PRRT) and somatostatin analogues (SSAs) are commonly combined as primary treatment for neuroendocrine neoplasms (NEN), and SSAs given as maintenance. We sought to evaluate whether sequential therapy with PRRT followed by SSAs has progression or survival benefits in patients with NEN after disease control by PRRT.

Methods: This prospective, randomised, single-centre study had as principal eligibility criteria: unresectable, locally advanced, or metastatic, histologically confirmed well-differentiated NEN; no symptoms/biochemical diagnosis of carcinoid syndrome; no SSAs or ≤ 3 months of SSAs before PRRT; and stable disease or partial or complete response after PRRT. Altogether, 115 patients were randomised 2:1 to an SSA group (n = 74) given octreotide acetate LAR every 4 weeks, or a control group (n = 41) receiving only best supportive care. Octreotide treatment was to stop upon intolerable toxicity or patient refusal, or, at physician/patient discretion, upon NEN progression. The primary endpoint was progression-free survival (PFS), the secondary endpoint, and overall survival (OS).

Results: Median (25th-75th percentile) follow-up from the first PRRT activity to death or latest observation was 6.6 (3.18-10.22) years. During that time, 71/115 patients (62%) progressed, 52/74 (70%) in the SSA group, and 19/41 (46%) in the control group (p = 0.01). Eighty-eight/115 patients (76%) died, 58/74 (78%) in the SSA group, and 30/41 (73%) in the control group (p = 0.52). Median (95% CI) PFS was 4.7 (2.8-7.7) years in the SSA group, and 6.4 (4.1-not reached) years in controls. Overall, median OS was 6.6 years. Neither PFS nor OS differed between groups (p = 0.129, p = 0.985, respectively).

Conclusions: In patients with disease control after PRRT, subsequent SSA treatment appeared not to be associated with better PFS or OS. Whether to continue SSA administration upon progression after PRRT requires evaluation in a prospective, randomised, controlled multicentre study with a relatively homogeneous sample.

Keywords: Neuroendocrine malignancies; Peptide receptor radionuclide therapy; Sequential treatment; Somatostatin analogues; Survival.

PubMed Disclaimer

References

    1. Reubi JC. Peptide receptor expression in GEP-NET [eng]. Virchows Arch. 2007;451 Suppl 1:S47–S50. https://doi.org/10.1007/s00428-007-0443-2 . - DOI - PubMed
    1. Ahlman H, Wängberg B, Nilsson O, Grimelius L, Granérus G, Modlin IM, et al. Aspects on diagnosis and treatment of the foregut carcinoid syndrome [eng]. Scand J Gastroenterol. 1992;27:59–71. https://doi.org/10.3109/00365529209000106 . - DOI - PubMed
    1. Oberg K, Ferone D, Kaltsas G, Knigge U-P, Taal B, Plöckinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy [eng]. Neuroendocrinology. 2009;90:09–213. https://doi.org/10.1159/000183751 . - DOI - PubMed
    1. Schally AV. Oncological applications of somatostatin analogues [eng]. Cancer Res. 1988;48(24 Pt 1):6977–85. - PubMed
    1. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family [eng]. Life Sci. 1995;57:9–65. https://doi.org/10.1016/0024-3205(95)02082-t . - DOI - PubMed

Publication types

LinkOut - more resources